The intricate world of pharmaceutical synthesis relies on a foundation of well-characterized and reliably sourced chemical intermediates. Among these, 4-[4-Fluoro-3-(piperazine-1-carbonyl)benzyl]phthalazin-1(2H)-one (CAS: 763111-47-3) stands out as a critical component, particularly in the production of the targeted cancer therapy, Olaparib. This article provides an in-depth look at the chemical properties, applications, and the importance of sourcing this intermediate from expert manufacturers.

As a leading manufacturer of fine chemicals and pharmaceutical intermediates, we understand the precise requirements for compounds like 4-[4-Fluoro-3-(piperazine-1-carbonyl)benzyl]phthalazin-1(2H)-one. This molecule, typically presented as a yellow to white solid, boasts a purity of ≥98%, ensuring its suitability for advanced pharmaceutical synthesis. Its molecular formula, C20H19FN4O2, and molecular weight of 366.39 g/mol, are crucial parameters for R&D scientists and formulation chemists to consider when planning synthetic routes.

The primary application for this intermediate is in the synthesis of Olaparib, a PARP inhibitor instrumental in treating certain types of cancer. The presence of fluorine and the piperazine moiety within its structure are key to its reactivity and effectiveness in the multistep synthesis of the final drug product. For pharmaceutical companies looking to buy high-quality intermediates, selecting a dependable supplier is paramount. We offer this compound at competitive prices, making it accessible for both research laboratories and large-scale production facilities.

When seeking an Olaparib intermediate manufacturer, consider our commitment to quality control and our robust supply chain capabilities. Sourcing from China through a trusted partner like us ensures you receive material that meets stringent specifications, facilitating smoother synthesis processes and potentially reducing lead times. We are dedicated to providing the chemical building blocks that empower groundbreaking pharmaceutical advancements.